Accueil   Diary - News   All news Long-term survival analysis shows a clear clinical benefit of inolimomab in SR-aGvHD

Long-term survival analysis shows a clear clinical benefit of inolimomab in SR-aGvHD

 

 

  • Follow-up of INO-107 Phase III study patients up to 8.5 yearsis the first long term analysis of a randomized study in acute steroid-resistant graft versus host disease (SR-aGvHD)

  • Investigators letter published in Blood Advances journal completes the result of the initial analysis of INO-107 study and demonstrates clinical benefit of inolimomab in SR-aGvHD

  • This analysis shows a clear superiority of inolimomab against anti-thymocyte globulin

 

Lyon, FRANCE, 23 January 2019, ELSALYS BIOTECH, a new player in immuno-oncology, presentsthe results from long-term follow-up of INO-107 Phase III study patients up to 8.5 years. These results have been published in a Letter to Blood signed by the investigators demonstrating clinical benefit of inolimomab (LEUKOTAC®) in acute steroid-resistant graft versus host disease (SR-aGvHD).

 

Read the press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree